TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TYK Medicines, Inc. Class H ( (HK:2410) ) has shared an announcement.
TYK Medicines, Inc has announced the convening of its second extraordinary general meeting (EGM) for 2025, scheduled for October 30. The meeting will address several key resolutions, including amendments to the rules of procedure for the Board of Directors and Shareholders’ General Meetings, changes to the Articles of Association, the abolishment of the Board of Supervisors, and the adoption of a 2025 H Share Incentive Scheme. These changes are likely to impact the company’s governance structure and shareholder engagement, potentially influencing its strategic direction and operational efficiency.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on developing and providing medicinal products and services, with a market presence in Hong Kong, as indicated by its listing on the Hong Kong Stock Exchange.
Average Trading Volume: 11,359,335
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.02B
See more insights into 2410 stock on TipRanks’ Stock Analysis page.